These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

821 related articles for article (PubMed ID: 22437504)

  • 1. Structure of the human κ-opioid receptor in complex with JDTic.
    Wu H; Wacker D; Mileni M; Katritch V; Han GW; Vardy E; Liu W; Thompson AA; Huang XP; Carroll FI; Mascarella SW; Westkaemper RB; Mosier PD; Roth BL; Cherezov V; Stevens RC
    Nature; 2012 Mar; 485(7398):327-32. PubMed ID: 22437504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elucidation of conformational states, dynamics, and mechanism of binding in human κ-opioid receptor complexes.
    Leonis G; Avramopoulos A; Salmas RE; Durdagi S; Yurtsever M; Papadopoulos MG
    J Chem Inf Model; 2014 Aug; 54(8):2294-308. PubMed ID: 25060329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective κ opioid antagonists nor-BNI, GNTI and JDTic have low affinities for non-opioid receptors and transporters.
    Munro TA; Huang XP; Inglese C; Perrone MG; Van't Veer A; Carroll FI; Béguin C; Carlezon WA; Colabufo NA; Cohen BM; Roth BL
    PLoS One; 2013; 8(8):e70701. PubMed ID: 23976952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Importance of phenolic address groups in opioid kappa receptor selective antagonists.
    Thomas JB; Fix SE; Rothman RB; Mascarella SW; Dersch CM; Cantrell BE; Zimmerman DM; Carroll FI
    J Med Chem; 2004 Feb; 47(4):1070-3. PubMed ID: 14761209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ligand/kappa-opioid receptor interactions: insights from the X-ray crystal structure.
    Martinez-Mayorga K; Byler KG; Yongye AB; Giulianotti MA; Dooley CT; Houghten RA
    Eur J Med Chem; 2013 Aug; 66():114-21. PubMed ID: 23792349
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of BU09059: a novel potent selective κ-receptor antagonist.
    Casal-Dominguez JJ; Furkert D; Ostovar M; Teintang L; Clark MJ; Traynor JR; Husbands SM; Bailey SJ
    ACS Chem Neurosci; 2014 Mar; 5(3):177-84. PubMed ID: 24410326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural biology: How opioid drugs bind to receptors.
    Filizola M; Devi LA
    Nature; 2012 May; 485(7398):314-7. PubMed ID: 22596150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological properties of JDTic: a novel kappa-opioid receptor antagonist.
    Carroll I; Thomas JB; Dykstra LA; Granger AL; Allen RM; Howard JL; Pollard GT; Aceto MD; Harris LS
    Eur J Pharmacol; 2004 Oct; 501(1-3):111-9. PubMed ID: 15464069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Michael acceptor approach to the design of new salvinorin A-based high affinity ligands for the kappa-opioid receptor.
    Polepally PR; Huben K; Vardy E; Setola V; Mosier PD; Roth BL; Zjawiony JK
    Eur J Med Chem; 2014 Oct; 85():818-29. PubMed ID: 25193297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Computational insights into the subtype selectivity and "message-address-efficacy" mechanisms of opioid receptors through JDTic binding and unbinding.
    Cheng JX; Cheng T; Li WH; Liu GX; Zhu WL; Tang Y
    Acta Pharmacol Sin; 2018 Mar; 39(3):482-491. PubMed ID: 29047460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Study of a structurally similar kappa opioid receptor agonist and antagonist pair by molecular dynamics simulations.
    Kolinski M; Filipek S
    J Mol Model; 2010 Oct; 16(10):1567-76. PubMed ID: 20195661
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigation of the selectivity of oxymorphone- and naltrexone-derived ligands via site-directed mutagenesis of opioid receptors: exploring the "address" recognition locus.
    Metzger TG; Paterlini MG; Ferguson DM; Portoghese PS
    J Med Chem; 2001 Mar; 44(6):857-62. PubMed ID: 11300867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potent and selective indolomorphinan antagonists of the kappa-opioid receptor.
    Stevens WC; Jones RM; Subramanian G; Metzger TG; Ferguson DM; Portoghese PS
    J Med Chem; 2000 Jul; 43(14):2759-69. PubMed ID: 10893314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis, and pharmacological evaluation of JDTic analogs to examine the significance of the 3- and 4-methyl substituents.
    Carroll FI; Gichinga MG; Kormos CM; Maitra R; Runyon SP; Thomas JB; Mascarella SW; Decker AM; Navarro HA
    Bioorg Med Chem; 2015 Oct; 23(19):6379-88. PubMed ID: 26342544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of (3R)-7-hydroxy-N-((1S)-1-[[(3R,4R)-4-(3-hydroxyphenyl)- 3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl)-1,2,3,4-tetrahydro- 3-isoquinolinecarboxamide as a novel potent and selective opioid kappa receptor antagonist.
    Thomas JB; Atkinson RN; Vinson NA; Catanzaro JL; Perretta CL; Fix SE; Mascarella SW; Rothman RB; Xu H; Dersch CM; Cantrell BE; Zimmerman DM; Carroll FI
    J Med Chem; 2003 Jul; 46(14):3127-37. PubMed ID: 12825951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Binding of norbinaltorphimine (norBNI) congeners to wild-type and mutant mu and kappa opioid receptors: molecular recognition loci for the pharmacophore and address components of kappa antagonists.
    Larson DL; Jones RM; Hjorth SA; Schwartz TW; Portoghese PS
    J Med Chem; 2000 Apr; 43(8):1573-6. PubMed ID: 10780914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kappa-opioid receptor-mediated effects of the plant-derived hallucinogen, salvinorin A, on inverted screen performance in the mouse.
    Fantegrossi WE; Kugle KM; Valdes LJ; Koreeda M; Woods JH
    Behav Pharmacol; 2005 Dec; 16(8):627-33. PubMed ID: 16286814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel fluoroalkyl derivatives of selective kappa opioid receptor antagonist JDTic: Design, synthesis, pharmacology and molecular modeling studies.
    Schmitt S; Colloc'h N; Perrio C
    Eur J Med Chem; 2015 Jan; 90():742-50. PubMed ID: 25513968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and in vitro opioid receptor functional antagonism of analogues of the selective kappa opioid receptor antagonist (3R)-7-hydroxy-N-((1S)-1-{[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl}-2-methylpropyl)-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide (JDTic).
    Cai TB; Zou Z; Thomas JB; Brieaddy L; Navarro HA; Carroll FI
    J Med Chem; 2008 Mar; 51(6):1849-60. PubMed ID: 18307295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacodynamic Relationships between Duration of Action of JDTic-like Kappa-Opioid Receptor Antagonists and Their Brain and Plasma Pharmacokinetics in Rats.
    Owens SM; Pollard GT; Howard JL; Fennell TR; Snyder RW; Carroll FI
    ACS Chem Neurosci; 2016 Dec; 7(12):1737-1745. PubMed ID: 27700049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.